In a new To the Point post, the Commonwealth Fund's Shawn Bishop explains that pharmaceutical manufacturers are putting pressure on Congress to make two changes: roll back the discount on brand-name drugs that manufacturers are required to offer beneficiaries in the Part D coverage "donut hole," and block an increase in the amount beneficiaries must spend in the donut hole before catastrophic coverage kicks in. "These proposals would financially benefit drug manufacturers more than Medicare beneficiaries," Bishop says.